<DOC>
	<DOC>NCT00448396</DOC>
	<brief_summary>To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.</brief_summary>
	<brief_title>Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria Age ≥ 18 years of age Life expectancy ≥3 months Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist Agents containing warfarin or heparin must be discontinued 7 days prior to enrollment in the study Exclusion criteria History of/or active bleeding disorders Known hypersensitivity to warfarin or related compounds The use of vitamin K Central lines that require anticoagulant maintenance The use of agents containing warfarin and heparin Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>EPO</keyword>
	<keyword>Patupilone</keyword>
	<keyword>Solid tumors</keyword>
	<keyword>Advanced malignancies</keyword>
</DOC>